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ABSTRACT
Tuberous sclerosis complex (TSC) is a genetic
multisystem disorder with prominent skin
involvement including facial angiofibromas
that often appear in early childhood. Here we
report the case of a 12-year-old girl with wide-
spread disfiguring facial angiofibromas that
were successfully treated with topical rapamy-
cin, a mTOR inhibitor. A sustained remission of
skin lesions was documented in detail over a
3-year follow-up. This case highlights the fact
that topical rapamycin is a useful option in
treating TSC-associated skin lesions. Especially
in medically complex patients topical treatment
may lessen the need for surgical interventions,
reducing the risks of surgery, its adverse effects
and permanent scarring. However, there is no
standard dose or formulation at present. Topical
rapamycin appears safe, but long-term mainte-
nance therapy is necessary to prevent facial
lesions from regrowth.
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INTRODUCTION
Tuberous sclerosis complex (TSC) is an autoso-
mal-dominant neurocutaneous disease charac-
terized by excess cell growth and proliferation,
resulting in benign tumors and other abnormal
tissue in multiple organs, including the skin [1, 2].
TSC is caused by inactivity of either of the two
tumor suppressor genes, TSC1 or TSC2, encoding
hamartin and tuberin [3, 4]. These proteins play
an important role in the control of cell prolifera-
tion and differentiation through negative regula-
tion of the mammalian target of rapamycin
complex 1 (mTORC1). mTORC1 inhibitors such
as rapamycin (sirolimus) or everolimus suppress
tumor growth by reestablishing inhibition of
mTORC1 and have been used as a targeted ther-
apy for non-dermatologic manifestations in TSC
(e.g., subependymal giant cell astrocytomas or
kidney angiomyolipomas) [5].
Facial angiofibroma, previously known as
‘adenoma sebaceum’, is the most common TSC
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
B887F0602946756B.
D. Ebrahimi-Fakhari  S. Meyer 
M. Flotats-Bastardas
Department of Pediatrics and Neonatology,
Saarland Tuberous Sclerosis Center, Saarland
University Medical Center, Homburg/Saar,
Germany
C. S. L. Mu¨ller (&)  T. Vogt  C. Pfo¨hler
Department of Dermatology, Allergology, and
Venereology, Saarland University Medical Center,
Homburg/Saar, Germany
e-mail: cornelia.mueller@uks.eu
Dermatol Ther (Heidelb) (2017) 7:175–179
DOI 10.1007/s13555-017-0174-5
lesion to occur on the face [6] and represents a
visible and often disfiguring stigma of the dis-
ease [7]. Invasive treatment options including
cryosurgery, curettage, dermabrasion, chemical
peeling, excision, and laser therapy are often
used to treat disfiguring or bleeding lesions [8].
Benefits of these invasive procedures have to be
balanced against the risks of permanent scar-
ring, sedation in medically complex patients
and incomplete removal of lesions as well as
costs. Off-label use of topical rapamycin has
been suggested as a non-invasive alterative
approach to treating facial angiofibromas in
pediatric TSC patients [9, 10].
CASE REPORT
We present a 12-year-old girl with a definitive
diagnosis of TSC (TSC2 mutation) [11] and
wide-spread disfiguring facial angiofibromas
(Fig. 1a, b). Other TSC-related manifestations
include subependymal nodules, focal epilepsy,
intellectual disability, autism spectrum
disorder, a cardiac rhabdomyoma, renal
angiomyolipoma, retinal astrocytoma, scoliosis
and primary enuresis. After obtaining consent,
the patient received a twice-daily treatment
every-day schedule with a 0.1% rapamycin
ointment. The 100 g ointment was com-
pounded by a local pharmacy, using 100 cru-
shed 1-mg sirolimus oral tablets, paraffin and
petrolatum.
This treatment regimen, started in August
2013, led to a marked reduction of angiofibro-
mas during the first 16 weeks (Fig. 1c). No
adverse effects were observed during the treat-
ment period, and negative plasma rapamycin
levels were reassuring against significant sys-
temic drug levels. After a course of almost
1 year, when almost all angiofibromas had
vanished (Fig. 2), the topical treatment was
discontinued for 3 months and recurrence was
evaluated. Previously faded angiofibromas were
found to reoccur (Fig. 3a). Therefore, topical
rapamycin therapy was restarted, again with a
marked treatment response (Fig. 3b). We evalu-
ated the increased size of previously faded
Fig. 1 Angioﬁbromas at baseline, prior to topical rapamycin treatment (a, b). Marked reduction of angioﬁbromas during
the ﬁrst 16 weeks of treatment (c)
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angiofibromas after discontinuing treatment
because of the patient’s adolescence and not for
any ‘rebound effect.’ At the time of this report,
the patient is still using the off-label medication
with good response. Informed consent was
obtained from the patient and her parents for
being included in the study.
CONCLUSION
Emerging evidence suggests that topical
mTORC1 inhibitors, such as rapamycin, appear
to be safe and effective treatment options for
TSC-related cutaneous manifestations,
although long-term outcome data are pending
[8]. To the best of our knowledge, this report of
a 3-year follow-up is the longest published to
date. Table 1 summarizes previously used topi-
cal rapamycin therapy for angiofibromas with at
least 6-month treatment regimes. Topical rapa-
mycin appears safe, but long-term maintenance
therapy is necessary to prevent facial lesions
from regrowth. There is only a single published
randomized controlled trial evaluating topical
rapamycin therapy versus placebo [12].
Although the subjects in the treatment arms
reported greater subjective improvement com-
pared to subjects in the placebo arm, the study
was not powered to reach statistical difference.
Therefore, further randomized controlled clini-
cal trials and direct comparison to invasive
Fig. 2 After a course of 1 year, angioﬁbromas have
disappeared almost completely
Fig. 3 Reoccurrence of previously faded angioﬁbromas after discontinuing treatment for nearly 3 months (a). Treatment
response after restarting topical rapamycin. Of note, the patient is starting to develop acne vulgaris (b)
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surgical treatment modalities are clearly desir-
able to establish the optimal treatment proto-
cols and dosage for topical mTORC1 inhibitors.
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